|Systematic (IUPAC) name|
|14px (what is this?)|
Fasiplon binds strongly to benzodiazepine sites on the GABAA receptor and has similar anxiolytic effects in animals, but with less sedative or muscle relaxant action. It was developed by a team at Roussel Uclaf in the 1990s
- Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991). "2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors". Journal of Medicinal Chemistry 34 (7): 2060–7. PMID 1648620. doi:10.1021/jm00111a021.
- US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making